1
|
Casas-Recasens S, Mendoza N, López-Giraldo A, Garcia T, Cosio BG, Pascual-Guardia S, Acosta-Castro A, Borras-Santos A, Gea J, Garrabou G, Agusti A, Faner R. Telomere Length but Not Mitochondrial DNA Copy Number Is Altered in Both Young and Old COPD. Front Med (Lausanne) 2021; 8:761767. [PMID: 34901077 PMCID: PMC8652089 DOI: 10.3389/fmed.2021.761767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Accepted: 10/13/2021] [Indexed: 11/13/2022] Open
Abstract
Accelerated ageing is implicated in the pathogenesis of respiratory diseases as chronic obstructive pulmonary disease (COPD), but recent evidence indicates that the COPD can have roots early in life. Here we hypothesise that the accelerated ageing markers might have a role in the pathobiology of young COPD. The objective of this study was to compare two hallmarks of ageing, telomere length (TL), and mitochondrial DNA copy number (mtDNA-CN, as a surrogate marker of mitochondrial dysfunction) in young (≤ 50 years) and old (>50 years) smokers, with and without COPD. Both, TL and mtDNA-CN were measured in whole blood DNA by quantitative PCR [qPCR] in: (1) young ever smokers with (n = 81) or without (n = 166) COPD; and (2) old ever smokers with (n = 159) or without (n = 29) COPD. A multivariable linear regression was used to assess the association of TL and mtDNA-CN with lung function. We observed that in the entire study population, TL and mtDNA-CN decreased with age, and the former but not the latter related to FEV1/FVC (%), FEV1 (% ref.), and DLCO (% ref.). The short telomeres were found both in the young and old patients with severe COPD (FEV1 <50% ref.). In addition, we found that TL and mtDNA-CN were significantly correlated, but their relationship was positive in younger while negative in the older patients with COPD, suggesting a mitochondrial dysfunction. We conclude that TL, but not mtDNA-CN, is associated with the lung function impairment. Both young and old patients with severe COPD have evidence of accelerated ageing (shorter TL) but differ in the direction of the correlation between TL and mtDNA-CN in relation to age.
Collapse
Affiliation(s)
- Sandra Casas-Recasens
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Nuria Mendoza
- Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Alejandra López-Giraldo
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Respiratory Institute, Hospital Clinic, Barcelona, Spain
| | - Tamara Garcia
- Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Borja G Cosio
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Department of Pneumology, University Hospital Son Espases, Palma de Mallorca, Spain.,Institut d'Investigació Sanitària Illes Balears (IdISBa), University Hospital Son Espases, Palma de Mallorca, Spain
| | - Sergi Pascual-Guardia
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Servei de Pneumologia, Hospital del Mar - IMIM, Barcelona, Spain.,Universitat Pompeu Fabra, Barcelona, Spain
| | - Ady Acosta-Castro
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Pulmonary Service and Research Institute, Doce de Octubre University Hospital, Madrid, Spain
| | - Alicia Borras-Santos
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,ISGlobal, Barcelona, Spain
| | - Joaquim Gea
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Servei de Pneumologia, Hospital del Mar - IMIM, Barcelona, Spain.,Universitat Pompeu Fabra, Barcelona, Spain
| | - Gloria Garrabou
- Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.,Muscle Research and Mitochondrial Function Laboratory, Internal Medicine Service, Hospital Clinic of Barcelona, Barcelona, Spain.,CIBERER-Spanish Biomedical Research Centre in Rare Diseases, Madrid, Spain
| | - Alvar Agusti
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Respiratory Institute, Hospital Clinic, Barcelona, Spain.,Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain
| | - Rosa Faner
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| |
Collapse
|
2
|
Molina-Molina M, Agusti A, Crestani B, Schwartz DA, Königshoff M, Chambers RC, Maher TM, Faner R, Mora AL, Rojas M, Antoniou KM, Sellares J. Towards a global initiative for fibrosis treatment (GIFT). ERJ Open Res 2017; 3:00106-2017. [PMID: 29214157 PMCID: PMC5710382 DOI: 10.1183/23120541.00106-2017] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2017] [Accepted: 10/06/2017] [Indexed: 12/13/2022] Open
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterised by increased scarring of lung tissue. Despite the recent introduction of novel drugs that slow disease progression, IPF remains a deadly disease, and the benefits of these new drugs differ markedly between patients. Human diseases arise due to alterations in an almost limitless network of interconnected genes, proteins, metabolites, cells and tissues, in direct relationship with a continuously changing macro- or microenvironment. Systems biology is a novel research strategy that seeks to understand the structure and behaviour of the so-called “emergent properties” of complex systems, such as those involved in disease pathogenesis, which are most often overlooked when just one element of disease pathogenesis is observed in isolation. This article summarises the debate that took place during a European Respiratory Society research seminar in Barcelona, Spain on December 15–16, 2016, which focused on how systems biology could generate new data by integrating the different IPF pathogenic levels of complexity. The main conclusion of the seminar was to create a global initiative to improve IPF outcomes by integrating cutting-edge international research that leverages systems biology to develop a precision medicine approach to tackle this devastating disease. A novel call to action for implementing systems biology in IPF researchhttp://ow.ly/Is0A30gpnVb
Collapse
Affiliation(s)
- Maria Molina-Molina
- Servei de Pneumologia, Laboratori de Pneumologia Experimental, IDIBELL, Campus de Bellvitge, Universitat de Barcelona, Barcelona, Spain.,CIBER of Respiratory Diseases, ISCIII, Barcelona, Spain
| | - Alvar Agusti
- CIBER of Respiratory Diseases, ISCIII, Barcelona, Spain.,Servei de Pneumologia, Institut Respiratori, Hospital Clinic, Universitat de Barcelona, IDIBAPS, Barcelona, Spain
| | - Bruno Crestani
- Service de Pneumologie A, Hospital Bichat, University Paris Diderot, Paris, France
| | | | - Melanie Königshoff
- Division of Pulmonary Sciences and Critical Care Medicine, Dept of Medicine, University of Colorado, Aurora, CO, USA
| | - Rachel C Chambers
- Centre for Inflammation and Tissue Repair, UCL Respiratory, University College London, London, UK
| | - Toby M Maher
- Interstitial Lung Disease Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK.,Fibrosis Research Group, National Heart and Lung Institute, Imperial College, London, UK
| | - Rosa Faner
- CIBER of Respiratory Diseases, ISCIII, Barcelona, Spain.,Servei de Pneumologia, Institut Respiratori, Hospital Clinic, Universitat de Barcelona, IDIBAPS, Barcelona, Spain
| | - Ana Lucia Mora
- Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.,Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, USA
| | - Mauricio Rojas
- Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.,The Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease, University of Pittsburgh, Pittsburgh, PA, USA
| | - Katerina M Antoniou
- Dept of Respiratory Medicine and Laboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, Heraklion, Greece
| | - Jacobo Sellares
- CIBER of Respiratory Diseases, ISCIII, Barcelona, Spain.,Servei de Pneumologia, Institut Respiratori, Hospital Clinic, Universitat de Barcelona, IDIBAPS, Barcelona, Spain
| |
Collapse
|
3
|
Agustí A, Bafadhel M, Beasley R, Bel EH, Faner R, Gibson PG, Louis R, McDonald VM, Sterk PJ, Thomas M, Vogelmeier C, Pavord ID. Precision medicine in airway diseases: moving to clinical practice. Eur Respir J 2017; 50:50/4/1701655. [PMID: 29051276 DOI: 10.1183/13993003.01655-2017] [Citation(s) in RCA: 138] [Impact Index Per Article: 19.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2017] [Accepted: 09/05/2017] [Indexed: 02/06/2023]
Abstract
On February 21, 2017, a European Respiratory Society research seminar held in Barcelona discussed how to best apply precision medicine to chronic airway diseases such as asthma and chronic obstructive pulmonary disease. It is now clear that both are complex and heterogeneous diseases, that often overlap and that both require individualised assessment and treatment. This paper summarises the presentations and discussions that took place during the seminar. Specifically, we discussed the need for a new taxonomy of human diseases, the role of different players in this scenario (exposome, genes, endotypes, phenotypes, biomarkers and treatable traits) and a number of unanswered key questions in the field. We also addressed how to deploy airway precision medicine in clinical practice today, both in primary and specialised care. Finally, we debated the type of research needed to move the field forward.
Collapse
Affiliation(s)
- Alvar Agustí
- Respiratory Institute, Hospital Clínic, Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain .,Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Spain
| | - Mona Bafadhel
- Dept of Respiratory Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Richard Beasley
- Medical Research Institute of New Zealand, Wellington, New Zealand
| | - Elisabeth H Bel
- Dept of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, The Netherlands
| | - Rosa Faner
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Spain
| | - Peter G Gibson
- The Centre of Excellence in Severe Asthma, Priority Research Centre for Healthy Lungs, The University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia
| | - Renaud Louis
- Pneumology Dept, CHU Liege, GIGA I3 research group, University of Liege, Liege, Belgium
| | - Vanessa M McDonald
- The Centre of Excellence in Severe Asthma, Priority Research Centre for Healthy Lungs, The University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia
| | - Peter J Sterk
- Dept of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, The Netherlands
| | - Mike Thomas
- Primary Care and Population Sciences, University of Southampton, Aldermoor Health Centre, Southampton, UK
| | - Claus Vogelmeier
- University of Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany
| | - Ian D Pavord
- Dept of Respiratory Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK.,Oxford NIHR Biomedical Research Centre, University of Oxford and Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | | |
Collapse
|
4
|
Faner R, Cruz T, Casserras T, López-Giraldo A, Noell G, Coca I, Tal-Singer R, Miller B, Rodriguez-Roisin R, Spira A, Kalko SG, Agustí A. Network Analysis of Lung Transcriptomics Reveals a Distinct B-Cell Signature in Emphysema. Am J Respir Crit Care Med 2017; 193:1242-53. [PMID: 26735770 DOI: 10.1164/rccm.201507-1311oc] [Citation(s) in RCA: 83] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
RATIONALE Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation caused by a combination of airways disease (bronchiolitis) and parenchymal destruction (emphysema), whose relative proportion varies from patient to patient. OBJECTIVES To explore and contrast the molecular pathogenesis of emphysema and bronchiolitis in COPD. METHODS We used network analysis of lung transcriptomics (Affymetrix arrays) in 70 former smokers with COPD to compare differential expression and gene coexpression in bronchiolitis and emphysema. MEASUREMENTS AND MAIN RESULTS We observed that in emphysema (but not in bronchiolitis) (1) up-regulated genes were enriched in ontologies related to B-cell homing and activation; (2) the immune coexpression network had a central core of B cell-related genes; (3) B-cell recruitment and immunoglobulin transcription genes (CXCL13, CCL19, and POU2AF1) correlated with emphysema severity; (4) there were lymphoid follicles (CD20(+)IgM(+)) with active B cells (phosphorylated nuclear factor-κB p65(+)), proliferation markers (Ki-67(+)), and class-switched B cells (IgG(+)); and (5) both TNFRSF17 mRNA and B cell-activating factor protein were up-regulated. These findings were by and large reproduced in a group of patients with incipient emphysema and when patients with emphysema were matched for the severity of airflow limitation of those with bronchiolitis. CONCLUSIONS Our study identifies enrichment in B cell-related genes in patients with COPD with emphysema that is absent in bronchiolitis. These observations contribute to a better understanding of COPD pathobiology and may open new therapeutic opportunities for patients with COPD.
Collapse
Affiliation(s)
- Rosa Faner
- 1 Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain.,2 Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain
| | - Tamara Cruz
- 1 Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain.,2 Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain
| | - Teresa Casserras
- 3 Bioinformatics Platform Institut d'investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | - Alejandra López-Giraldo
- 1 Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain.,2 Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain
| | - Guillaume Noell
- 2 Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain
| | - Ignacio Coca
- 1 Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain
| | | | | | - Roberto Rodriguez-Roisin
- 1 Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain.,2 Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain.,5 Respiratory Institute, Pulmonary Service, Hospital Clinic, Institut d'investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; and
| | - Avrum Spira
- 6 Boston University School of Medicine, Boston, Massachusetts
| | - Susana G Kalko
- 3 Bioinformatics Platform Institut d'investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | - Alvar Agustí
- 1 Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain.,2 Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain.,5 Respiratory Institute, Pulmonary Service, Hospital Clinic, Institut d'investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; and
| |
Collapse
|
5
|
Faner R, Sobradillo P, Noguera A, Gomez C, Cruz T, López-Giraldo A, Ballester E, Soler N, Arostegui JI, Pelegrín P, Rodriguez-Roisin R, Yagüe J, Cosio BG, Juan M, Agustí A. The inflammasome pathway in stable COPD and acute exacerbations. ERJ Open Res 2016; 2:00002-2016. [PMID: 27730204 PMCID: PMC5034597 DOI: 10.1183/23120541.00002-2016] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2016] [Accepted: 05/17/2016] [Indexed: 01/06/2023] Open
Abstract
Chronic obstructive pulmonary disease (COPD) is characterised by pulmonary and systemic inflammation that bursts during exacerbations of the disease (ECOPD). The NLRP3 inflammasome is a key regulatory molecule of the inflammatory response. Its role in COPD is unclear. We investigated the NLRP3 inflammasome status in: 1) lung tissue samples from 38 patients with stable COPD, 15 smokers with normal spirometry and 14 never-smokers; and 2) sputum and plasma samples from 56 ECOPD patients, of whom 41 could be reassessed at clinical recovery. We observed that: 1) in lung tissue samples of stable COPD patients, NLRP3 and interleukin (IL)-1β mRNA were upregulated, but both caspase-1 and ASC were mostly in inactive form, and 2) during infectious ECOPD, caspase-1, oligomeric ASC and associated cytokines (IL-1β, IL-18) were significantly increased in sputum compared with clinical recovery. The NLRP3 inflammasome is primed, but not activated, in the lungs of clinically stable COPD patients. Inflammasome activation occurs during infectious ECOPD. The results of this study suggest that the inflammasome participates in the inflammatory burst of infectious ECOPD. The NLRP3 inflammasome is primed in stable COPD lungs, then activated during infectious exacerbationhttp://ow.ly/Wopi300DXcT
Collapse
Affiliation(s)
- Rosa Faner
- Fundació Clinic per a la Recerca Biomèdica, Barcelona, Spain; CIBER Respiratory Diseases (CIBERES), Barcelona, Spain; These authors contributed equally to this work
| | - Patricia Sobradillo
- CIBER Respiratory Diseases (CIBERES), Barcelona, Spain; Pulmonary Service, Hospital Txagorritxu, Vitoria, Spain; These authors contributed equally to this work
| | - Aina Noguera
- CIBER Respiratory Diseases (CIBERES), Barcelona, Spain; University Hospital Son Espases-IdISPa, Palma de Mallorca, Spain
| | - Cristina Gomez
- University Hospital Son Espases-IdISPa, Palma de Mallorca, Spain
| | - Tamara Cruz
- Fundació Clinic per a la Recerca Biomèdica, Barcelona, Spain; CIBER Respiratory Diseases (CIBERES), Barcelona, Spain
| | - Alejandra López-Giraldo
- Fundació Clinic per a la Recerca Biomèdica, Barcelona, Spain; CIBER Respiratory Diseases (CIBERES), Barcelona, Spain
| | - Eugeni Ballester
- Institut Respiratori, Hospital Clinic, Barcelona, Spain; Biomedic Research Institute August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Nestor Soler
- Institut Respiratori, Hospital Clinic, Barcelona, Spain; Biomedic Research Institute August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Juan I Arostegui
- Biomedic Research Institute August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Immunology Dept, Hospital Clinic, Barcelona, Spain
| | - Pablo Pelegrín
- Inflammation and Experimental Surgery Unit, CIBERHED, Murcia's BioHealth, Research Institute IMIB-Arrixaca, University Hospital Virgen de la Arrixaca, Murcia, Spain
| | - Roberto Rodriguez-Roisin
- CIBER Respiratory Diseases (CIBERES), Barcelona, Spain; Institut Respiratori, Hospital Clinic, Barcelona, Spain; Biomedic Research Institute August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Jordi Yagüe
- Biomedic Research Institute August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Immunology Dept, Hospital Clinic, Barcelona, Spain
| | - Borja G Cosio
- CIBER Respiratory Diseases (CIBERES), Barcelona, Spain; University Hospital Son Espases-IdISPa, Palma de Mallorca, Spain
| | - Manel Juan
- Biomedic Research Institute August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Immunology Dept, Hospital Clinic, Barcelona, Spain
| | - Alvar Agustí
- Fundació Clinic per a la Recerca Biomèdica, Barcelona, Spain; CIBER Respiratory Diseases (CIBERES), Barcelona, Spain; Institut Respiratori, Hospital Clinic, Barcelona, Spain; Biomedic Research Institute August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| |
Collapse
|
6
|
Monsó E, Montuenga LM, Sánchez de Cos J, Villena C. Biological Marker Analysis as Part of the CIBERES-RTIC Cancer-SEPAR Strategic Project on Lung Cancer. ACTA ACUST UNITED AC 2015. [DOI: 10.1016/j.arbr.2015.05.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
7
|
Monsó E, Montuenga LM, Sánchez de Cos J, Villena C. Biological Marker Analysis as Part of the CIBERES-RTIC Cancer-SEPAR Strategic Project on Lung Cancer. Arch Bronconeumol 2015; 51:462-7. [PMID: 25614375 DOI: 10.1016/j.arbres.2014.11.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2014] [Revised: 11/11/2014] [Accepted: 11/13/2014] [Indexed: 01/20/2023]
Abstract
The aim of the Clinical and Molecular Staging of Stage I-IIp Lung Cancer Project is to identify molecular variables that improve the prognostic and predictive accuracy of TMN classification in stage I/IIp non-small cell lung cancer (NSCLC). Clinical data and lung tissue, tumor and blood samples will be collected from 3 patient cohorts created for this purpose. The prognostic protein signature will be validated from these samples, and micro-RNA, ALK, Ros1, Pdl-1, and TKT, TKTL1 y G6PD expression will be analyzed. Tissue inflammatory markers and stromal cell markers will also be analyzed. Methylation of p16, DAPK, RASSF1a, APC and CDH13 genes in the tissue samples will be determined, and inflammatory markers in peripheral blood will also be analyzed. Variables that improve the prognostic and predictive accuracy of TNM in NSCLC by molecular staging may be identified from this extensive analytical panel.
Collapse
Affiliation(s)
- Eduard Monsó
- Servicio de Neumología Hospital Universitari Parc Taulí, Sabadell, España; CIBER de Enfermedades Respiratorias-CIBERES, Instituto de Salud Carlos III, Madrid, España.
| | - Luis M Montuenga
- Programa de Patogénesis de Tumores Sólidos, Laboratorio de Biomarcadores, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Grupo RTICC RD12/0036/0040, Pamplona, España; Departamentos de Histología y Anatomía Patológica, Facultades de Medicina y Ciencias, Universidad de Navarra, Pamplona, España
| | - Julio Sánchez de Cos
- CIBER de Enfermedades Respiratorias-CIBERES, Instituto de Salud Carlos III, Madrid, España; Servicio de Neumología, Hospital San Pedro de Alcántara, Cáceres, España
| | - Cristina Villena
- CIBER de Enfermedades Respiratorias-CIBERES, Instituto de Salud Carlos III, Madrid, España
| | | |
Collapse
|
8
|
Noguera A, Gomez C, Faner R, Cosio B, González-Périz A, Clària J, Carvajal A, Agustí A. An investigation of the resolution of inflammation (catabasis) in COPD. Respir Res 2012; 13:101. [PMID: 23148928 PMCID: PMC3546860 DOI: 10.1186/1465-9921-13-101] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2012] [Accepted: 11/06/2012] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Chronic Obstructive Pulmonary Disease (COPD) is characterized by an enhanced inflammatory response to smoking that persists despite quitting. The resolution of inflammation (catabasis) is a complex and highly regulated process where tissue resident macrophages play a key role since they phagocytose apoptotic cells (efferocytosis), preventing their secondary necrosis and the spill-over of their pro-inflammatory cytoplasmic content, and release pro-resolution and tissue repair molecules, such as TGFβ, VEGF and HGF. Because inflammation does not resolve in COPD, we hypothesized that catabasis may be abnormal in these patients. METHODS To explore this hypothesis, we studied lung tissue samples obtained at surgery from 21 COPD patients, 22 smokers with normal spirometry and 13 non-smokers controls. In these samples we used: (1) immunohistochemistry to assess the expression of CD44, CD36, VEGF and TGFβ in lung macrophages; (2) real time PCR to determine HGF, PPARγ, TGFβ, VEGF and MMP-9 gene expression; and, (3) ELISA to quantify lipoxin A4, a lipid mediator of catabasis. RESULTS We found that current and former smokers with COPD showed: (1) more inflammation (higher MMP-9 expression); (2) reduced macrophage surface expression of CD44, a key efferocytosis receptor; and, (3) similar levels of TGFβ, VEGF, HGF, PPARγ, and lipoxin A4 than smokers with normal spirometry, despite the presence of inflammation and disease. CONCLUSIONS These results identify several potential abnormalities of catabasis in patients with COPD.
Collapse
Affiliation(s)
- Aina Noguera
- Hospital Universitario Son Espases, Palma de Mallorca, Spain
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Herpel E, Koleganova N, Schreiber B, Walter B, Kalle CV, Schirmacher P. Structural requirements of research tissue banks derived from standardized project surveillance. Virchows Arch 2012; 461:79-86. [DOI: 10.1007/s00428-012-1258-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2012] [Revised: 04/17/2012] [Accepted: 05/21/2012] [Indexed: 10/27/2022]
|